| Provenge (sipuleucel-T) / Bausch Health |
NCT01133704: Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer |
|
|
| Completed | 3 | 98 | US | sipuleucel-T, APC-Placebo | Dendreon | Hormone-Refractory Prostate Cancer | 03/03 | 05/05 | | |
NCT00005947: Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
|
|
| Completed | 3 | 127 | US | sipuleucel-T, APC8015, Provenge, Placebo | Dendreon | Prostate Cancer | 09/04 | 09/04 | | |
| Completed | 3 | 176 | US | Control, Sipuleucel-T, Provenge®, APC8015 | Dendreon | Prostate Cancer | 08/06 | 05/15 | | |
NCT00065442: Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy |
|
|
| Completed | 3 | 512 | US, Canada | Sipuleucel-T, APC-Placebo | Dendreon | Prostate Cancer | 01/09 | 01/09 | | |
ProvONE, NCT06134232: Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T |
|
|
| Not yet recruiting | 3 | 400 | NA | Sipuleucel-T Injection | Dendreon | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/31 | 06/32 | | |
ProVent, NCT03686683: Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer |
|
|
| Active, not recruiting | 3 | 450 | US | sipuleucel-T | Dendreon, PRA Health Sciences | Adenocarcinoma of the Prostate | 12/23 | 02/24 | | |
